You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer

https://doi.org/10.1136/ebm.14.4.105

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    STUDY DESIGN

    Design:

    randomised controlled trial (European Randomised Study of Screening for Prostate Cancer [ERSPC]). Current Controlled Trials ISRCTN49127736.

    Allocation:

    not concealed, at least in part.* In 3 countries, randomisation occurred before consent was obtained; in the other 4 countries, only consenting participants were randomised, but allocation concealment was unclear.

    Blinding:

    blinded (outcome adjudication committees).*

    STUDY QUESTION

    Setting:

    7 European countries.

    Participants:

    162 243 men 55–69 years of age (mean age 61 y). Some countries also enrolled …

    View Full Text

    Footnotes

    • *See glossary.

      Abstract and commentary also appear in ACP Journal Club.

    • Source of funding: Europe Against Cancer; Fifth and Sixth Framework Program of the European Union; Beckman Coulter; local agencies and health authorities in participating countries.